CorMedix Inc. is a pharmaceutical company that develops and seeks to commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as Cardiorenal disease. Specifically, our goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications - in effect, "Treating the kidney to treat the heart.
Our therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy.
Click here to listen to what a key opinion leader has to say about contrast induced acute kidney injury and the role catalytic iron and oxidative stress play in cardiovascular disease:
Peter McCullough, MD, MPH Consultant Cardiologist, Chief Academic and Scientific Officer with St. John Providence Health System
Click here to listen to what a key opinion leader has to say about chronic kidney disease and catalytic iron:
Sudir Shah, MD, Professor of Medicine, Director of Nephrology University of Arkansas College of Medicine, Little Rock, AR
Click here to listen to a key opinion leader commenting on catheter related bloodstream infections, how they affect the dialysis patient population and current treatments available:
Michael Allon, MD, University of Alabama Birmingham, Birmingham Alabama
